-
AURKB in Pulmonary Hypertension: Study Insights
2026-09-30
Lemay et al. combined transcriptomic analysis, connectivity mapping, cellular experiments, animal models, and human precision-cut lung slices to identify AURKB as a potential driver of pulmonary arterial smooth muscle cell pathology. Pharmacological AURKB inhibition with barasertib reduced vascular remodeling and improved hemodynamics in established pulmonary hypertension models, while p21 attenuation produced an additional benefit.
-
PEI MW 40,000 for Mechanistic Gene Studies
2026-09-30
A translational perspective on how Polyethylenimine Linear (PEI), MW 40,000 can support causal gene perturbation, stress-response analysis, and scalable in vitro models of arsenic-induced blood-testis barrier injury.
-
OMV mRNA Antigen Display for Personalized Tumor Vaccines
2026-09-29
The 2022 Advanced Materials study developed engineered outer membrane vesicles that rapidly capture sequence-tagged mRNA antigens and deliver them to dendritic cells for cross-presentation. Its Plug-and-Display design produced antitumor activity, complete tumor regression in a subset of mice, and durable immune memory, while also highlighting important manufacturing and translational questions for personalized mRNA vaccines.
-
Amyloid β-Peptide (1-42): Applied Assay Workflows
2026-09-29
Build more interpretable Alzheimer’s disease models with Aβ42 peptide workflows spanning neuronal viability, ion-channel analysis, and microglial phagocytosis. This guide emphasizes preparation state, vehicle controls, aggregation-aware assay design, and practical troubleshooting for reproducible results.
-
Olive Biophenols and Aβ42 Pathology
2026-09-28
The reference study connects olive biophenols with reduced Aβ42-associated toxicity in SH-SY5Y cells and lower plaque deposition in an APPswe/PS1dE9 mouse model. Its main contribution is a combined cell–animal evaluation of oleuropein-rich interventions under both conventional and metal-associated amyloid conditions, while also highlighting unresolved questions about mechanism, bioavailability, and blood–brain barrier permeability.
-
Chlorambucil: DNA Crosslinking and Assay Design
2026-09-28
Chlorambucil is a nitrogen mustard alkylating agent that forms DNA crosslinks and can inhibit DNA replication. This research-focused overview separates product specifications from assay interpretation and explains why growth inhibition should not be treated as a direct measure of cell death.
-
Carboplatin Workflows for Resistance Research
2026-09-27
Use Carboplatin to build reproducible dose-response and resistance assays, then extend the workflow to cancer stem-like cell models. A 2025 TNBC study links IGF2BP3–FZD1/7 signaling to carboplatin resistance and offers a practical rationale for testing pathway-directed combinations rather than assuming every combination will improve response.
-
Nanoparticle RNAi Delivery in Bemisia tabaci
2026-09-26
The study reports a C60/alkylpolyglucoside (APG) nanocarrier that improved dsRNA-mediated silencing of two survival-related genes in the whitefly Bemisia tabaci. The findings support further evaluation of nanoparticle-assisted RNAi for pest management, while leaving important questions about dose, field performance, and delivery consistency to be resolved.
-
PP2A, Autophagy, and Candida Biofilm Drug Resistance
2026-09-25
A 2025 study links the PP2A catalytic-subunit gene PPH21 to autophagy, biofilm formation, and antifungal resistance in Candida albicans. Its genetic, pharmacological, and mouse-model findings position PP2A-associated regulation of Atg13 and Atg1 as a candidate mechanism, while leaving important questions about pathway detail and clinical transferability open.
-
Rg1 Restores Gut–Immune–Brain Signaling After Anesthesia
2026-09-25
In a mouse model of prolonged isoflurane exposure, Ginsenoside Rg1 improved behavioral, inflammatory, synaptic, and intestinal-barrier measures associated with neuroimmune disruption. Regulatory T-cell depletion removed these benefits, supporting a Treg-dependent gut–immune–brain mechanism while leaving clinical efficacy and several molecular pathways unresolved.
-
Amphotericin B: Sterol Biology to Translation
2026-09-24
Amphotericin B is more than a fungal-killing benchmark: its sterol-dependent membrane activity offers a way to test how target availability, immune signaling, and assay design shape translational conclusions. Recent Candida albicans research points to a potentiation strategy while underscoring the need for careful experimental boundaries.
-
BCKAs Activate HIF1α in Normoxic Vascular Cells
2026-09-24
A 2024 bioRxiv preprint reports that branched-chain α-ketoacids (BCKAs) can activate HIF1α signaling in vascular cells under normal oxygen conditions. The proposed mechanism links BCKA signaling to reduced PHD2 activity, increased glycolysis, and smooth-muscle-cell phenotypic changes relevant to pulmonary arterial hypertension.
-
Dorsomorphin (Compound C) for AMPK Workflows
2026-09-23
Use Dorsomorphin (Compound C) to test how AMPK inhibition reshapes metabolic, autophagic, and BMP/SMAD readouts—while designing controls that separate these pathways. This practical guide pairs a macrophage-inflammation research finding with a cautious, dose-titrated workflow for cell-based experiments.
-
Methoxy-X04 for Amyloid Imaging Workflows
2026-09-23
Methoxy-X04 is a brain-permeable fluorescent amyloid beta probe for rapid plaque, fibril, oligomer, and cerebrovascular amyloid readouts in Alzheimer’s disease models. This guide connects practical imaging workflows with the latest exercise–microglia–extracellular-vesicle mechanism while clearly separating validated product properties from recommended assay starting points.
-
MALAT1–miR-125b–STAT3 Axis in Sepsis
2026-09-22
The reference study proposes that MALAT1 increases procalcitonin expression in sepsis by regulating the miR-125b/STAT3 axis. Its combination of patient samples, an LPS-stimulated U937 model, RNA-interaction assays, and pathway perturbation provides a mechanistic framework for interpreting PCT regulation, while also highlighting limits in translating cell-based findings to clinical diagnosis.